Added to YB: 2026-06-15
Pitch date: 2026-06-10
MLYS [neutral]
Mineralys Therapeutics, Inc.
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States.
Market Cap
$1.9B
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-7.60
P/E
-11.68
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Show full summary:
GS Healthcare Conference – Recap (Day 2 – Part 2) - Mineralys Therapeutics, Inc.
MLYS (overview): Pre-commercial biotech prepping lorundrostat launch ahead of PDUFA this year for hypertension; targeting 4th-line patients first, plus CKD/kidney upside via UACR. Completed $200M Tanabe royalty buyback. Commercial org ~90 days from launch. M&A candidate as cardiorenal-metabolic interest grows.
Read full article (1 min)